Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE5530 + Atorvastatin in Primary Hypercholesterolemia
NCT00741715Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Aug 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Canosimibe in hypercholesterolemia (15 arms), sponsored by Sanofi. Primary endpoint: Percent change from baseline in calculated LDL-C at 12 weeks. Started Aug 2008; status: terminated.
02
Drugs
Canosimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00741715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741715.